Marker vaccine strategies and candidate CSFV marker vaccines

Vaccine

Volumn 25, Issue 2, 2007, Pages 205-230

  Dong, Xiao Nan ^a   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Classical swine fever (CSF); Diagnostic test; Marker vaccine

Indexed keywords

AUTOPROTEINASE; BAYOVAC; BCG VACCINE; CD40 LIGAND; CPG OLIGODEOXYNUCLEOTIDE; CRYSTAL VIOLET; DNA VACCINE; EMULSIFYING AGENT; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HERPESVIRUS VECTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 3; ISA 206; LIVE VACCINE; NONSTRUCTURAL PROTEIN 3; PEPTIDE VACCINE; PESTIVIRUS VACCINE; PORCILIS; PROTEINASE; RECOMBINANT CHIMERIC VACCINE; RECOMBINANT DELETION VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNINDEXED DRUG; VIRUS VACCINE; VIRUS VECTOR; WATER OIL CREAM;

ANIMAL HUSBANDRY; BACULOVIRUS EXPRESSION SYSTEM; CELLULAR IMMUNITY; CHIMERA; CONGENITAL INFECTION; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECONOMIC ASPECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; EXPRESSION VECTOR; GENE DELETION; HUMORAL IMMUNITY; LOW DRUG DOSE; MORTALITY; NONHUMAN; PERINATAL PERIOD; PESTIVIRUS; POLICY; PRIORITY JOURNAL; REVIEW; SEROLOGY; SWINE DISEASE; VACCINATION; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; CLASSICAL SWINE FEVER; CLASSICAL SWINE FEVER VIRUS; SEROLOGIC TESTS; SWINE; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 33845288971     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.07.033     Document Type: Review

References (191)

1. Moennig V. Introduction to classical swine fever: virus, disease and control policy. Vet Microbiol 73 (2000) 93-102
2. OIE. Disease Information dated 15 July, 2005;18(28):201.
3. Francki RIB, Fauquet CM, Knudson DL, Brown F., editors. Classification and nomenclature of viruses. Fifth report of the international committee on the taxonomy of viruses. Arch Virol 1991;Suppl 2:223-33.
4. Thiel H.J., Stark R., Weiland E., Rumenapf T., and Meyers G. Hog cholera virus: molecular composition of virions from a pestivirus. J Virol 65 9 (1991) 4705-4712
5. Rumenapf T., Unger G., Strauss J.H., and Thiel H.J. Processing of the envelope glycoproteins of pestiviruses. J Virol 67 6 (1993) 3288-3294
6. Xu J., Mendez E., Caron P.R., Lin C., Murcko M.A., Collett M.S., et al. Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication. J Virol 71 7 (1997) 5312-5322
7. rns and E2 at the cell surface and on isolated particles. J Gen Virol 80 Pt 5 (1999) 1157-1165
8. rns and E2 interact with different receptors. J Gen Virol 78 Pt 11 (1997) 2779-2787
9. Elbers K., Tautz N., Becher P., Stoll D., Rumenapf T., and Thiel H.J. Processing in the pestivirus E2-NS2 region: identification of proteins p7 and E2p7. J Virol 70 6 (1996) 4131-4315
10. Tamura J.K., Warrener P., and Collett M.S. RNA-stimulated NTPase activity associated with the p80 protein of the pestivirus bovine viral diarrhea virus. Virology 193 1 (1993) 1-10
11. Warrener P., and Collett M.S. Pestivirus NS3 (p80) protein possesses RNA helicase activity. J Virol 69 3 (1995) 1720-1726
12. Wiskerchen M., and Collett M.S. Pestivirus gene expression: protein p80 of bovine viral diarrhea virus is a proteinase involved in polyprotein processing. Virology 184 1 (1991) 341-350
13. Weiland E., Stark R., Haas B., Rumenapf T., Meyers G., and Thiel H.J. Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide-linked heterodimer. J Virol 64 8 (1990) 3563-3569
14. Kimman T.G., Bianchi A.T., Wensvoort G., de Bruin T.G., and Meliefste C. Cellular immune response to hog cholera virus (HCV): T cells of immune pigs proliferate in vitro upon stimulation with live HCV, but the E1 envelope glycoprotein is not a major T-cell antigen. J Virol 67 5 (1993) 2922-2927
15. Ceppi M., de Bruin M.G., Seuberlich T., Balmelli C., Pascolo S., Ruggli N., et al. Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells. J Gen Virol 86 Pt 9 (2005) 2525-2534
16. Risatti G.R., Borca M.V., Kutish G.F., Lu Z., Holinka L.G., French R.A., et al. The E2 glycoprotein of classical swine fever virus is a virulence determinant in swine. J Virol 79 6 (2005) 3787-3796
17. Weiland E., Ahl R., Stark R., Weiland F., and Thiel H.J. A second envelope glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J Virol 66 6 (1992) 3677-3682
18. Schneider R., Unger G., Stark R., Schneider-Scherzer E., and Thiel H.J. Identification of a structural glycoprotein of an RNA virus as a ribonuclease. Science 261 5125 (1993) 1169-1171
19. rns of the pestivirus classical swine fever virus lead to virus attenuation. J Virol 73 12 (1999) 10224-10235
20. van Gennip H.G., Vlot A.C., Hulst M.M., De Smit A.J., and Moormann R.J. Determinants of virulence of classical swine fever virus strain Brescia. J Virol 78 16 (2004) 8812-8823
21. Schweinitz E.A., and Dorset M. New facts concerning the etiology of hog cholera. 20th annual report of the bureau of animal industry (1904), US Department of Agriculture p. 157-62
22. Saulmon E.E. Hog cholera eradication: dream or reality. J Am Vet Med Assoc 163 9 (1973) 1103-1105
23. Koprowski H., James T.R., and Cox H.R. Propagation of hog cholera virus in rabbits. Proc Soc Exp Biol Med 63 (1946) 178-183
24. Baker J.A. Serial passage of hog cholera virus in rabbits. Proc Soc Exp Biol Med 63 (1946) 183-187
25. Lin T.C., Shieh C.M., and Su J.F. Virus multiplication in pigs inoculated with lapinized hog cholera live vaccine. Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi 7 1 (1974) 13-19 In Chinese
26. Lin T.T.C., and Lee R.C.T. An overall report on the development of a highly safe and potent lapinized hog cholera virus strain for hog cholera control in Taiwan. Natl Sci Coun Spec Publ 5 (1981) 1-44
27. Zhou T.C. Classical swine fever virus and progresses in its control (Part I). Chin J Vet Sci Technol 4 (1980) 23-33 [in Chinese]
28. Zhou T.C. Classical swine fever virus and progresses in its control (Part II). Chin J Vet Sci Technol 5 (1980) 30-39 [in Chinese]
29. Bognar K., and Meszaros J. Experiences with a lapinized hog cholera virus strain of decreased virulence. Acta Vet Acad Sci Hung 13 4 (1963) 429-438
30. Olah P., and Palatka Z. Immunobiological study of lapinized hog cholera virus strains. Acta Vet Acad Sci Hung 17 3 (1967) 239-247
31. Sasahara J., Kumagai T., Shimizu Y., and Furuuchi S. Field experiments of hog cholera live vaccine prepared in guinea-pig kidney cell culture. Natl Inst Anim Health Q (Tokyo) 9 Summer(2) (1969) 83-91
32. Sasahara J. Hog cholera: diagnosis and prophylaxis. Natl Inst Anim Health Q (Tokyo) 10 Winter(Suppl.) (1970) 57-81
33. Aynaud J.M., Lejolly J.C., Bibard C., and Galicher C. Studies of the properties of cold induced classical swine fever virus mutants. Application to vaccination. Bull Off Int Epizoot 75 9 (1971) 654-659 [in French]
34. Lunais M., and Aynud J.M. Classical swine fever: properties of a clone (strain "Thiverval") isolated from a cellular culture at a low temperature: application in vaccination. Rev Med Vet (Toulouse) 123 12 (1972) 1537-1554 [in French]
35. Lunais M., Aynud J.M., Corthier G., and Laude H. Swine fever: Characteristics of immunity, innocuity for pregnant sows and genetic stability of the "Thiverval" strain. Rev Med Vet (Toulouse) 125 2 (1974) 175-194 [in French]
36. Lunais M., and Aynud J.M. Classical swine fever: duration of immunity obtained in the sow with "Thiverval" strain under field conditions. Recl Med Vet 153 5 (1977) 349-352 [in French]
37. Lunais M., Aynud J.M., and Corthier G. Hog cholera virus: active immunization with the Thiverval strain in the presence and absence of colostral passive immunity. Vet Microbiol 3 (1978) 31-43
38. van Oirschot J.T. Vaccinology of classical swine fever: from lab to field. Vet Microbiol 96 4 (2003) 367-384
39. Genghini R., Tiranti I., Segade G., Amado J., Wittouck P., and Mian L. In vivo effect on pig chromosomes of high dosage vaccine against classic swine fever. Mutat Res 422 2 (1998) 357-365
40. Genghini R., Tiranti I., and Wittouck P. Pig chromosome aberrations after vaccination against classical swine fever in field trials. Vaccine 20 23-24 (2002) 2873-2877
41. rns of pestiviruses induces apoptosis in lymphocytes of several species. J Virol 71 9 (1997) 6692-6696
42. Vandeputte J., and Chappuis G. Classical swine fever: the European experience and a guide for infected areas. Rev Sci Tech 18 3 (1999) 638-647
43. Ellis P.R., James A.D., and Shaw A.P. Studies on the epidemiology and economics of swine fever eradication in the EEC. EUR 5738e (1977), Commission of the European Communities, Brussels, Belgium
44. Court of Auditors of the European Communities. Special Report No. 1/2000 on classical swine fever, together with the Commission's replies. Official Journal C 085; 23 March 2000. p. 0001-28.
45. The Council of European Economic Community. Council Directive 80/217/EEC of 22 January 1980 introducing Community measures for the control of classical swine fever. Official Journal L 047; 21 February 1980. p. 0011-23.
46. The Council of European Economic Community. Council Directive 80/1095/EEC of 11 November 1980 laying down conditions designed to render and keep the territory of the Community free from classical swine fever. Official Journal L 325; 01 December 1980. p. 0001-4.
47. The Council of European Economic Community. Council Directive 91/685/EEC of 11 December 1991 amending Directive 80/217/EEC introducing Community measures for the control of classical swine-fever. Official Journal L 377; 31 December 1991. p. 0001-14.
48. Stegeman A., Elbers A., de Smit H., Moser H., Smak J., and Pluimers F. The 1997-1998 epidemic of classical swine fever in the Netherlands. Vet Microbiol 73 2-3 (2000) 183-196
49. Meuwissen M.P., Horst S.H., Huirne R.B., and Dijkhuizen A.A. A model to estimate the financial consequences of classical swine fever outbreaks: principles and outcomes. Prev Vet Med 42 3-4 (1999) 249-270
50. van Oirschot J.T., Gielkens A.L., Moormann R.J., and Berns A.J. Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease. Vet Microbiol 23 1-4 (1990) 85-101
51. van Oirschot J.T., Kaashoek M.J., Rijsewijk F.A., and Stegeman J.A. The use of marker vaccines in eradication of herpesviruses. J Biotechnol 44 1-3 (1996) 75-81
52. Mangen M.J., Nielen M., and Burrell A.M. Simulated effect of pig-population density on epidemic size and choice of control strategy for classical swine fever epidemics in The Netherlands. Prev Vet Med 56 2 (1996) 141-163
53. Mangen M.J., Jalvingh A.W., Nielen M., Mourits M.C., Klinkenberg D., and Dijkhuizen A.A. Spatial and stochastic simulation to compare two emergency-vaccination strategies with a marker vaccine in the 1997/1998 Dutch Classical Swine Fever epidemic. Prev Vet Med 48 3 (2001) 177-200
54. The Council of European Community. Council Directive 2001/89/EC of 23 October 2001 on Community measures for the control of classical swine fever (text with EEA relevance). Official Journal L 316. 01 December 2001. p. 0005-35.
55. van Oirschot J.T. Diva vaccines that reduce virus transmission. J Biotechnol 73 2-3 (1999) 195-205
56. Walders B., Raschke A., Neugebauer M., Geuther E., Bertling W., Reiser C., et al. Blending of a conventional Mycoplasma hyopneumoniae vaccine with a positive marker: tracking of immunised pigs by peptide-specific antibodies raised to the marker component. Res Vet Sci 78 2 (2005) 135-141
57. Miner J.N., and Hruby D.E. Vaccinia virus: a versatile tool for molecular biologists. Trends Biotechnol 8 1 (1990) 20-25
58. Hruby D.E. Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin Microbiol Rev 3 2 (1990) 153-170
59. Rumenapf T., Stark R., Meyers G., and Thiel H.J. Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity. J Virol 65 2 (1991) 589-597
60. König M., Lengsfeld T., Pauly T., Stark R., and Thiel H.J. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J Virol 69 10 (1995) 6479-6486
61. Kaplan C. Vaccinia virus: a suitable vehicle for recombinant vaccines?. Arch Virol 106 1-2 (1989) 127-139
62. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 1 (1992) 217-232
63. Konishi E., Pincus S., Paoletti E., Laegreid W.W., Shope R.E., and Mason P.W. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 190 1 (1992) 454-458
64. Brockmeier S.L., Lager K.M., Tartaglia J., Riviere M., Paoletti E., and Mengeling W.L. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet Microbiol 38 1-2 (1993) 41-58
65. Taylor J., Weinberg R., Languet B., Desmettre P., and Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6 6 (1988) 497-503
66. Baxby D., and Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine 10 1 (1992) 8-9
67. Elahi S., Bergeron J., Nagy E., Talbot B.G., Harpin S., Shen S.H., et al. Induction of humoral and cellular immune responses in mice by. FEMS Microbiol Lett 171 2 (1999) 107-114
68. Hahn J., Park S.H., Song J.Y., An S.H., and Ahn B.Y. Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein. J Virol Methods 93 1-2 (2001) 49-56
69. Tuboly T., Nagy E., and Derbyshire J.B. Potential viral vectors for the stimulation of mucosal antibody responses against enteric viral antigens in pigs. Res Vet Sci 54 3 (1993) 345-350
70. Rziha H., Henkel M., Cottone R., Bauer B., Auge U., Gotz F., et al. Generation of recombinant parapoxviruses: non-essential genes suitable for insertion and expression of foreign genes. J Biotechnol 83 1-2 (2000) 137-145
71. Le Potier M., Mérant C., Voigt H., Wienhold D., Hutet E., Cariolet R., et al. Comparative assessment of baculovirus, DNA and parapoxvirus vector-mediated vaccination with E2 subunit against classical swine fever. Abstracts of the sixth ESVV pestivirus symposium. Thun, Switzerland, September 13-16th (2005) 50 P5-10
72. Thomsen D.R., Marotti K.R., Palermo D.P., and Post L.E. Pseudorabies virus as a live virus vector for expression of foreign genes. Gene 57 2-3 (1987) 261-265
73. Moormann R.J., de Rover T., Briaire J., Peeters B.P., Gielkens A.L., and van Oirschot J.T. Inactivation of the thymidine kinase gene of a gI deletion mutant of pseudorabies virus generates a safe but still highly immunogenic vaccine strain. J Gen Virol 71 Pt 7 (1990) 1591-1595
74. van Zijl M., Wensvoort G., de Kluyver E., Hulst M., van der Gulden H., Gielkens A., et al. Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera. J Virol 65 5 (1991) 2761-2765
75. Hooft van Iddekinge B.J., de Wind N., Wensvoort G., Kimman T.G., Gielkens A.L., and Moormann R.J. Comparison of the protective efficacy of recombinant pseudorabies viruses against pseudorabies and classical swine fever in pigs; influence of different promoters on gene expression and on protection. Vaccine 14 1 (1996) 6-12
76. Mulder W.A., Priem J., Glazenburg K.L., Wagenaar F., Gruys E., Gielkens A.L., et al. Virulence and pathogenesis of non-virulent and virulent strains of pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus. J Gen Virol 75 Pt 1 (1994) 117-124
77. Peeters B., Bienkowska-Szewczyk K., Hulst M., Gielkens A., and Kimman T. Biologically safe, non-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever. J Gen Virol 78 Pt 12 (1997) 3311-3315
78. Mulder W., Pol J., Kimman T., Kok G., Priem J., and Peeters B. Glycoprotein D-negative pseudorabies virus can spread transneuronally via direct neuron-to-neuron transmission in its natural host, the pig, but not after additional inactivation of gE or gI. J Virol 70 4 (1996) 2191-2200
79. Moormann R.J., van Gennip H.G., Miedema G.K., Hulst M.M., and van Rijn P.A. Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. J Virol 70 2 (1996) 763-770
80. Derbyshire J.B., Clarke M.C., and Collins A.P. Serological and pathogenicity studies with some unclassified porcine adenoviruses. J Comp Pathol 85 3 (1975) 437-443
81. Hirahara T., Yasuhara H., Matsui O., Yamanaka M., Tanaka M., Fukuyama S., et al. Isolation of porcine adenovirus from the respiratory tract of pigs in Japan. Nippon Juigaku Zasshi 52 2 (1990) 407-409
82. Hammond J.M., and Johnson M.A. Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics. Vet J 169 1 (2005) 17-27
83. Reddy P.S., Idamakanti N., Hyun B.H., Tikoo S.K., and Babiuk L.A. Development of porcine adenovirus-3 as an expression vector. J Gen Virol 80 Pt 3 (1999) 563-570
84. Reddy P.S., Idamakanti N., Babiuk L.A., Mehtali M., and Tikoo S.K. Porcine adenovirus-3 as a helper-dependent expression vector. J Gen Virol 80 Pt 11 (1999) 2909-2916
85. Hammond J.M., McCoy R.J., Jansen E.S., Morrissy C.J., Hodgson A.L., and Johnson M.A. Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 18 11-12 (2000) 1040-1050
86. Tuboly T., and Nagy E. Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene. J Gen Virol 82 Pt 1 (2001) 183-190
87. Zakhartchouk A., Zhou Y., and Tikoo S.K. A recombinant E1-deleted porcine adenovirus-3 as an expression vector. Virology 313 2 (2003) 377-386
88. Hammond J.M., Jansen E.S., Morrissy C.J., Williamson M.M., Hodgson A.L., and Johnson M.A. Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene. Arch Virol 146 9 (2001) 1787-1793
89. Hammond J.M., Jansen E.S., Morrissy C.J., Hodgson A.L., and Johnson M.A. Protection of pigs against 'in contact' challenge with classical swine fever following oral or subcutaneous vaccination with a recombinant porcine adenovirus. Virus Res 97 2 (2003) 151-157
90. Becher P., Avalos Ramirez R., Orlich M., Cedillo Rosales S., Konig M., Schweizer M., et al. Genetic and antigenic characterization of novel pestivirus genotypes: implications for classification. Virology 311 1 (2003) 96-104
91. Depner K.R., and Schirrmeier H. Inoculation of pigs with BDV or BVDV-2 and subsequent challenge with CSFV. Abstracts of the fifth ESVV pestivirus symposium. Cambridge, United Kingdom, August 26-29th (2002) 63
92. Reimann I., Depner K., Trapp S., and Beer M. An avirulent chimeric Pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus. Virology 322 1 (2004) 143-157
93. Beer M, Kaaden V, Depner K, Kramer M, Staubach C, Lange E, et al. Individual progress report of the programme, Epidemiology and control of classical swine fever in wild boar and potential use of a newly developed live marker vaccine, (SSPE-CT-2003-501599) for the period from 01 January 2004 to 31 January 2005.
94. Rasmussen T., Uttenthal A., Nielsen J., Beer M., Depner K., and Reimann I. Virulence, immunogenicity and vaccine properties of a novel chimeric pestivirus. Abstracts of the sixth ESVV pestivirus symposium. Thun, Switzerland, September 13-16th (2005) 83 P5-6
95. Liang D., Sainz I.F., Ansari I.H., Gil L.H., Vassilev V., and Donis R.O. The envelope glycoprotein E2 is a determinant of cell culture tropism in ruminant pestiviruses. J Gen Virol 84 Pt 5 (2003) 1269-1274
96. Corapi W.V., Donis R.O., and Dubovi E.J. Monoclonal antibody analyses of cytopathic and noncytopathic viruses from fatal bovine viral diarrhea virus infections. J Virol 62 8 (1988) 2823-2827
97. Becher P., Orlich M., and Thiel H.J. RNA recombination between persisting pestivirus and a vaccine strain: generation of cytopathogenic virus and induction of lethal disease. J Virol 75 14 (2001) 6256-6264
98. Becher P., Orlich M., and Thiel H.J. Mutations in the 5′ nontranslated region of bovine viral diarrhea virus result in altered growth characteristics. J Virol 74 17 (2000) 7884-7894
99. Makoschey B., Becher P., Janssen M.G., Orlich M., Thiel H.J., and Lutticken D. Bovine viral diarrhea virus with deletions in the 5′-nontranslated region: reduction of replication in calves and induction of protective immunity. Vaccine 22 25-26 (2004) 3285-3294
100. Wensvoort G., Terpstra C., de Kluijver E.P., Kragten C., and Warnaar J.C. Antigenic differentiation of pestivirus strains with monoclonal antibodies against hog cholera virus. Vet Microbiol 21 1 (1989) 9-20
101. Edwards S., Moennig V., and Wensvoort G. The development of an international reference panel of monoclonal antibodies for the differentiation of hog cholera virus from other pestiviruses. Vet Microbiol 29 2 (1991) 101-108
102. Kosmidou A., Ahl R., Thiel H.J., and Weiland E. Differentiation of classical swine fever virus (CSFV) strains using monoclonal antibodies against structural glycoproteins. Vet Microbiol 47 1-2 (1995) 111-118
103. de Smit A.J., van Gennip H.G., Miedema G.K., van Rijn P.A., Terpstra C., and Moormann R.J. Recombinant classical swine fever (CSF) viruses derived from the Chinese vaccine strain (C-strain) of CSF virus retain their avirulent and immunogenic characteristics. Vaccine 18 22 (2000) 2351-2358
104. rns deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines. J Virol 74 7 (2000) 2973-2980
105. rns or E2 of CSFV. Vaccine 20 11-12 (2002) 1544-1556
106. Wensvoort G. Topographical and functional mapping of epitopes on hog cholera virus with monoclonal antibodies. J Gen Virol 70 Pt 11 (1989) 2865-2876
107. rns gene: a potential marker vaccine for intradermal application. Vet Res 37 5 (2006) 655-670
108. Maurer R., Stettler P., Ruggli N., Hofmann M.A., and Tratschin J.D. Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV. Vaccine 23 25 (2005) 3318-3328
109. Yu M., Wang L.F., Shiell B.J., Morrissy C.J., and Westbury H.A. Fine mapping of a C-terminal linear epitope highly conserved among the major envelope glycoprotein E2 (gp51 to gp54) of different pestiviruses. Virology 222 1 (1996) 289-292
110. Lin M., Lin F., Mallory M., and Clavijo A. Deletions of structural glycoprotein E2 of classical swine fever virus strain Alfort/187 resolve a linear epitope of monoclonal antibody WH303 and the minimal N-terminal domain essential for binding immunoglobulin G antibodies of a pig hyperimmune serum. J Virol 74 24 (2000) 11619-11625
111. rns or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response. Vaccine 19 4-5 (2000) 447-459
112. Wensvoort G., Terpstra C., and de Kluyver E.P. Characterization of porcine and some ruminant pestiviruses by cross-neutralization. Vet Microbiol 20 4 (1989) 291-306
113. Dekker A., Wensvoort G., and Terpstra C. Six antigenic groups within the genus pestivirus as identified by cross neutralization assays. Vet Microbiol 47 3-4 (1995) 317-329
114. de Smit A.J., Bouma A., van Gennip H.G., de Kluijver E.P., and Moormann R.J. Chimeric (marker) C-strain viruses induce clinical protection against virulent classical swine fever virus (CSFV) and reduce transmission of CSFV between vaccinated pigs. Vaccine 19 11-12 (2001) 1467-1476
115. Wehrle F., Bossy S., and Hofmann M. Chimeric pestiviruses: candidates for live attenuated CSF marker vaccines. Chimeric pestivirus recombinants were constructed based on the widely used CSFV vaccine strain Riems. Abstracts of the sixth pestivirus symposium. Thun, Switzerland, September 13-16th (2005) 85 P5-8
116. Risatti G., Holinka L., Lu Z., Kutish G., Rock D., and Borca M. Chimeric classical swine fever virus containing the E2 gene from a vaccine strain in the genetic background of strain Brescia induces solid early protection in swine. Abstracts of the sixth pestivirus symposium. Thun, Switzerland, September 13-16th (2005) 87 P5-10
117. Risatti G.R., Holinka L.G., Lu Z., Kutish G.F., Tulman E.R., French R.A., et al. Mutation of E1 glycoprotein of classical swine fever virus affects viral virulence in swine. Virology 343 (2005) 116-127
118. Stark R., Meyers G., Rumenapf T., and Thiel H.J. Processing of pestivirus polyprotein: cleavage site between autoprotease and nucleocapsid protein of classical swine fever virus. J Virol 67 12 (1993) 7088-7095
119. pro. J Virol 77 13 (2003) 7645-7654
120. pro. J Virol 79 11 (2005) 7239-7247
121. pro of classical swine fever virus is an antagonist of double-stranded RNA-mediated apoptosis and IFN-alpha/beta induction. Virology 340 2 (2005) 265-276
122. pro of classical swine fever virus in the activation of monocyte-derived dendritic cells. Virology 343 1 (2005) 93-105
123. pro is not required for viral replication in cell culture. J Virol 72 9 (1998) 7681-7684
124. pro gene. Vaccine 22 3-4 (2004) 317-328
125. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 247 4949 Pt 1 (1990) 1465-1468
126. Tang D.C., DeVit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 6365 (1992) 152-154
127. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 5102 (1993) 1745-1749
128. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Annu Rev Immunol 15 (1997) 617-648
129. Andrew M.E., Morrissy C.J., Lenghaus C., Oke P.G., Sproat K.W., Hodgson A.L., et al. Protection of pigs against classical swine fever with DNA-delivered gp55. Vaccine 18 18 (2000) 1932-1938
130. Hammond J.M., Jansen E.S., Morrissy C.J., Goff W.V., Meehan G.C., Williamson M.M., et al. A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever. Vet Microbiol 80 2 (2001) 101-119
131. Andrew M., Morris K., Coupar B., Sproat K., Oke P., Bruce M., et al. Porcine interleukin-3 enhances DNA vaccination against classical swine fever. Vaccine 24 16 (2006) 3241-3247
132. Wienhold D., Armengol E., Marquardt A., Marquardt C., Voigt H., Buttner M., et al. Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination. Vet Res 36 4 (2005) 571-587
133. Nobiron I., Thompson I., Brownlie J., and Collins M.E. Co-administration of IL-2 enhances antigen-specific immune responses following vaccination with DNA encoding the glycoprotein E2 of bovine viral diarrhoea virus. Vet Microbiol 76 2 (2000) 129-142
134. Nobiron I., Thompson I., Brownlie J., and Collins M.E. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice. Vaccine 19 30 (2001) 4226-4235
135. Nobiron I., Thompson I., Brownlie J., and Collins M.E. DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge. Vaccine 21 17-18 (2003) 2082-2092
136. Mutwiri G., Pontarollo R., Babiuk S., Griebel P., van Drunen Littel-van den Hurk S., Mena A., et al. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol 91 2 (2003) 89-103
137. Zhang S., Guo Y.J., Sun S.H., Wang K.Y., Wang K.H., Zhang Y., et al. DNA vaccination using bacillus-Calmette-Guerin-DNA as an adjuvant to enhance immune response to three kinds of swine diseases. Scand J Immunol 62 4 (2005) 371-377
138. Ganges L., Barrera M., Nunez J.I., Blanco I., Frias M.T., Rodriguez F., et al. DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge. Vaccine 23 28 (2005) 3741-3752
139. Yu X., Tu C., Li H., Hu R., Chen C., Li Z., et al. DNA-mediated protection against classical swine fever virus. Vaccine 19 11-12 (2001) 1520-1525
140. Markowska-Daniel I., Collins R.A., and Pejsak Z. Evaluation of genetic vaccine against classical swine fever. Vaccine 19 17-19 (2001) 2480-2484
141. Moormann R.J.M., van Rijn P.A., de Smit A.J., Wensvoort G., and Terpstra C. Recent developments in pig vaccinology. Proceedings of the 14th international pig veterinary society (IPVS) congress. Bologne, Italy, 7-14th July (1996) 25-28
142. de Smit A.J. Laboratory diagnosis, epizootiology, and efficacy of marker vaccines in classical swine fever: a review. Vet Q 22 4 (2000) 182-188
143. Hulst M.M., Westra D.F., Wensvoort G., and Moormann R.J. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. J Virol 67 9 (1993) 5435-5442
144. Bouma A., de Smit A.J., de Kluijver E.P., Terpstra C., and Moormann R.J. Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Vet Microbiol 66 2 (1999) 101-114
145. Bouma A., De Smit A.J., De Jong M.C., De Kluijver E.P., and Moormann R.J. Determination of the onset of the herd-immunity induced by the E2 sub-unit vaccine against classical swine fever virus. Vaccine 18 14 (2000) 1374-1381
146. Moormann R.J., Bouma A., Kramps J.A., Terpstra C., and De Smit H.J. Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Vet Microbiol 73 2-3 (2000) 209-219
147. de Smit A.J., Bouma A., de Kluijver E.P., Terpstra C., and Moormann R.J. Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination. Vet Microbiol 78 4 (2001) 307-317
148. de Smit A.J., Bouma A., de Kluijver E.P., Terpstra C., and Moormann R.J. Prevention of transplacental transmission of moderate-virulent classical swine fever virus after single or double vaccination with an E2 subunit vaccine. Vet Q 22 3 (2000) 150-153
149. Klinkenberg D., Moormann R.J., de Smit A.J., Bouma A., and de Jong M.C. Influence of maternal antibodies on efficacy of a subunit vaccine: transmission of classical swine fever virus between pigs vaccinated at 2 weeks of age. Vaccine 20 23-24 (2002) 3005-3013
150. Terzic S., Jemersic L., Lojkic M., Madic J., Grom J., Toplak I., et al. Comparison of antibody values in sera of pigs vaccinated with a subunit or an attenuated vaccine against classical swine fever. Vet Res Commun 27 4 (2003) 329-339
151. Lipowski A., Drexler C., and Pejsak Z. Safety and efficacy of a classical swine fever subunit vaccine in pregnant sows and their offspring. Vet Microbiol 77 1-2 (2000) 99-108
152. Ahrens U., Kaden V., Drexler C., and Visser N. Efficacy of the classical swine fever (CSF) marker vaccine Porcilis Pesti in pregnant sows. Vet Microbiol 77 1-2 (2000) 83-97
153. Dewulf J., Laevens H., Koenen F., Mintiens K., and de Kruif A. An E2 sub-unit marker vaccine does not prevent horizontal or vertical transmission of classical swine fever virus. Vaccine 20 1-2 (2001) 86-91
154. Dewulf J., Koenen F., Ribbens S., Haegeman A., Laevens H., and De Kruif A. Evaluation of the epidemiological importance of classical swine fever infected, E2 sub-unit marker vaccinated animals with RT-nPCR positive blood samples. J Vet Med B Infect Dis Vet Publ Health 52 9 (2005) 367-371
155. Dewulf J., Laevens H., Koenen F., Mintiens K., and de Kruif A. Efficacy of E2-sub-unit marker and C-strain vaccines in reducing horizontal transmission of classical swine fever virus in weaner pigs. Prev Vet Med 65 3-4 (2004) 121-133
156. Ziegler U., and Kaden V. Vaccination of weaner pigs against classical swine fever with the subunit vaccine "Porcilis Pesti": influence of different immunization plans on excretion and transmission of challenge virus. Berl Munch Tierarztl Wochenschr 115 7-8 (2002) 267-273 [in German]
157. Dewulf J., Laevens H., Koenen F., Vanderhallen H., Mintiens K., Deluyker H., et al. An experimental infection with classical swine fever in E2 sub-unit marker-vaccine vaccinated and in non-vaccinated pigs. Vaccine
158. Uttenthal A., Le Potier M.F., Romero L., De Mia G.M., and Floegel-Niesmann G. Classical swine fever (CSF) marker vaccine. Trial I. Challenge studies in weaner pigs. Vet Microbiol 83 2 (2001) 85-106
159. Depner K.R., Bouma A., Koenen F., Klinkenberg D., Lange E., de Smit H., et al. Classical swine fever (CSF) marker vaccine. Trial II. Challenge study in pregnant sows. Vet Microbiol 83 2 (2001) 107-120
160. Floegel-Niesmann G. Classical swine fever (CSF) marker vaccine. Trial III. Evaluation of discriminatory ELISAs. Vet Microbiol 83 2 (2001) 121-136
161. van Rijn P.A., van Gennip H.G., de Meijer E.J., and Moormann R.J. Epitope mapping of envelope glycoprotein E1 of Hog cholera virus strain Brescia. J Gen Virol 74 Pt 10 (1993) 2053-2060
162. van Rijn P.A., Miedema G.K., Wensvoort G., van Gennip H.G., and Moormann R.J. Antigenic structure of envelope glycoprotein E1 of hog cholera virus. J Virol 68 (1994) 3934-3942
163. van Rijn P.A., Bossers A., Wensvoort G., and Moormann R.J. Classical swine fever virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV challenge. J Gen Virol 77 Pt 11 (1996) 2737-2745
164. van Rijn P.A., van Gennip H.G., and Moormann R.J. An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV). Vaccine 17 5 (1999) 433-440
165. Wong M.L., Liu J.J., Chang Y., and Chang T.J. Expression of the glycoprotein E2 of the classical swine fever virus in Escherichia coli. J Vet Med Sci 60 4 (1998) 541-544
166. Yu X.L., Tu C.C., Xu X.R., Zhang M.L., Chen Y.X., and Liu B.H. Site-directed mutagensis of the major antigen E2 gene of CSFV, its high level expression in Escherichia coli and the immunonicity of recombinant E2 protein. Sheng Wu Gong Cheng Xue Bao 19 4 (2003) 439-443 [in Chinese]
167. Kesik M., Saczynska V., Szewczyk B., and Plucienniczak A. Inclusion bodies from recombinant bacteria as a novel system for delivery of vaccine antigen by the oral route. Immunol Lett 91 2-3 (2004) 197-204
168. Pauly T., Elbers K., Konig M., Lengsfeld T., Saalmuller A., and Thiel H.J. Classical swine fever virus-specific cytotoxic T lymphocytes and identification of a T cell epitope. J Gen Virol 76 Pt 12 (1995) 3039-3049
169. Armengol E., Wiesmuller K.H., Wienhold D., Buttner M., Pfaff E., Jung G., et al. Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus. J Gen Virol 83 Pt 3 (2002) 551-560
170. Rau H., Revets H., Balmelli C., McCullough K.C., and Summerfield A. Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo. Vet Res 37 1 (2006) 155-168
171. Rau H., Revets H., Cornelis P., Titzmann A., Ruggli N., McCullough K.C., et al. Related Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever. Vaccine 24 22 (2006) 4757-4768
172. Legocki A.B., Miedzinska K., Czaplinska M., Plucieniczak A., and Wedrychowicz H. Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine 23 15 (2005) 1844-1846
173. Hollinger F.B., Dreesman G.R., Sparrow J., and Melnick J.L. Synthetic peptide vaccine for hepatitis B. Dev Biol Stand 54 (1983) 113-116
174. Schoolnik G.K., Tai J.Y., and Gotschlich E.C. A pilus peptide vaccine for the prevention of gonorrhea. Prog Allergy 33 (1983) 314-331
175. Klipstein F.A., Engert R.F., and Houghten R.A. Immunisation of volunteers with a synthetic peptide vaccine for enterotoxigenic Escherichia coli. Lancet 1 8479 (1986) 471-472
176. Zavala F., Tam J.P., Barr P.J., Romero P.J., Ley V., Nussenzweig R.S., et al. Synthetic peptide vaccine confers protection against murine malaria. J Exp Med 166 5 (1987) 1591-1596
177. Dong X.N., Wei K., Liu Z.Q., and Chen Y.H. Candidate peptide vaccine induced protection against classical swine fever virus. Vaccine 21 3-4 (2002) 167-173
178. Dong X.N., Chen Y., Wu Y., and Chen Y.H. Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker. Vaccine 23 28 (2005) 3630-3633
179. Dong X.N., and Chen Y.H. Strategies for mapping neutralizing epitopes: one way and two sides. Vaccine 24 22 (2006) 4689-4691
180. Eickhoff T.C., and Myers M. Workshop summary-aluminum in vaccines. Vaccine 20 Suppl. 3 (2002) S1-S4
181. Baylor N.W., Egan W., and Richman P. Aluminum salts in vaccines-US perspective. Vaccine 20 Suppl. 3 (2002) S18-S23
182. Dong X.N., Qi Y., Ying J., Chen X., and Chen Y.H. Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2. Vaccine 24 4 (2006) 426-434
183. Dong X.N., and Chen Y.H. Spying the neutralizing epitopes on E2 N-terminal by candidate epitope-vaccines against classical swine fever virus. Vaccine 24 19 (2006) 4029-4034
184. Dong X.N., and Chen Y.H. Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2. Vaccine 24 11 (2006) 1906-1913
185. Liu S., Tu C., Wang C., Yu X., Wu J., Guo S., et al. The protective immune response induced by B cell epitope of classical swine fever virus glycoprotein E2. J Virol Methods 134 1-2 (2006) 125-129
186. Christmann A., Wentzel A., Meyer C., Meyers G., and Kolmar H. Epitope mapping and affinity purification of monospecific antibodies by Escherichia coli cell surface display of gene-derived random peptide libraries. J Immunol Methods 257 1-2 (2001) 163-173
187. rns protein for pig antibodies elicited during classical swine fever virus infection. J Biochem (Tokyo) 136 6 (2004) 795-804
188. rns fragments after infection with classical swine fever virus. Clin Diagn Lab Immunol 12 1 (2005) 180-186
189. rns using phage-displayed random peptide library. Arch Virol 151 1 (2006) 37-54
190. Roberts M. Evaluation of optimal size of restriction zones in disease control with particular references to classical swine fever. Proceedings of meeting of the society for veterinary epidemiology and preventive medicine. Reading, UK, 29-31 March (1995) 119-130
191. Stegeman A., Elbers A.R., Smak J., and de Jong M.C. Quantification of the transmission of classical swine fever virus between herds during the 1997-1998 epidemic in The Netherlands. Prev Vet Med 42 3-4 (1999) 219-234